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1Introduction
A survey carried out by YouGov in 2013 showed 
that less than one ﬁfth of respondents in the UK 
(out of 4034 randomly approached UK adults) 
believed that the pharmaceutical industry is 
trustworthy, with one respondent admitting 
concern as to “motives and actions” of those 
involved in the industry (YouGov, 2013). While 
this is a relatively small sample corresponding 
to less than 1% of the total UK population (ONS, 
2013) and is therefore not representative of 
the majority's opinions, it serves as an illustra-
tive example of the public's views of the 
industry, especially as all respondents were 
random and not targeted. 
Studies carried out into the sector (primarily in 
the US and Canadian markets, although other 
major markets including the UK are considered 
in the study's conclusions) have shown that 
while the quality of the service provided is vital 
in ensuring public usage, a sense of trust will be 
non-existent without a basic level of corporate 
integrity with the public (Perepelkin and Di 
Zhang, 2014). The pharmaceutical industry is 
perceived by many to be lacking in this respect 
as companies are often seen focusing on 
making money from the sick rather than curing 
them, through extortionate prices and market-
ing schemes supported through the patent 
system. While this is an assumption drawn upon 
from the Australian system, it is concluded that 
it is relevant for the majority of global pharma-
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2ceutical markets, including the UK's 
(Moynihan, Heath and Henry, 2002), mak-
ing it a relevant addition to this study.
The patent system used by the pharmaceu-
tical industry provides signiﬁcant mone-
tary incentive while protecting those 
innovations for a 20-year period. Upon 
expiration, the knowledge enters the 
public domain and smaller companies can 
sell their versions at a reduced price. 
Signiﬁcant increases in global market 
pricing by 127% between 2008-2014 for 
blockbuster pharmaceuticals (Jensen, 
2018), promoted by high research and 
development costs equating to $2.6 billion 
(Sullivan, 2019), is a direct result of 
increasing patent coverage. A recent study 
found that 70% of Americans considered 
these price hikes ample proof of pharma-
ceutical companies putting proﬁt before 
patients (Loftstedt, 2007; Valverde, 2012).
The standard research and development 
process followed by pharmaceutical 
companies in the development of new 
drugs is shown in Figure 1. While the Ameri-
can healthcare system and patent system 
diﬀer considerably from the ones used in 
the United Kingdom, it is still relevant to 
draw on comparisons between the two. 
The US has a privatised, insurance-based 
healthcare system requiring large cost 
from patients attributing to the negative 
views held by the 70% of surveyed Ameri-
cans (Gallup, 2018). By comparison, the 
United Kingdom has a nationalised health 
service in which the cost to the patient is 
mostly free at the point-of-care. 
Increasingly, media coverage of the phar-
maceutical industry focuses on the proﬁts 
of individual companies rather than any 
successes in developing new (Hinsliﬀ, 
2008) such that a staggering 69.5% of 
media headlines (globally) about the 
pharmaceutical industry in 2004 were 
negative (Sillup and Porth, 2007). This 
presents an interesting state of aﬀairs in 
which overwhelmingly negative media 
coverage may could be used to inﬂuence 
the views towards the pharmaceutical 
industry. As of April 2019, there was no 
published peer-reviewed literature explic-
itly exploring the eﬀect of certain demo-
graphics (education, age, gender and 
location) on the public perceptions of the 
pharmaceutical industry how these inﬂu-
ence  t he  buy i ng  p re fe rence  f o r 
generic/own-brand or branded over-the-
counter painkillers, and whether providing 
extra information will inﬂuence these 
opinions. 
The use of generic pharmaceuticals over 
branded variants has been found to have 
no noticeable negative impact on the 
quality of treatment and yet there 
remains a market for branded products 
(Kwon, Lee and Kwon, 2008; Duerden and 
Hughes, 2010). The reasons for this are 
many with some research suggesting 
availability of funds and education both 
have an impact on purchasing choice 
(Valverde, 2008; Halme, Linden and 
Kaaria, 2009; Crigger et al., 2009). While 
this has been explored in the Indian 
Pharmaceutical Market, how these 
factors apply to the British market has 
not been evaluated (Sanyal and Datta, 
2011). Exploring how perceptions and 
understanding diﬀer across diﬀerent 
societies, cultures and economic settings 
could be vital in understanding the role 
of the pharmaceutical industry today, and 
how these inﬂuence their functions and 
methods of sale.
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Figure 1: Typical Drug Research and Development Timeline
3Aims
The purpose of this research was to explore 
how the provision of information has the 
potential to alter and inﬂuence public 
opinion of the pharmaceutical industry. 
Additionally, this study aimed to determine 
the reasons why there is a tendency to 
purchase branded drugs rather than, the 
often cheaper, generic versions. Speciﬁc 
demographics, such as education, age, 
gender, and location and their ability to 
inﬂuence public opinion towards the 
pharmaceutical industry were considered 
as part of this study. 
Methodology
Data Collection
A Google Form questionnaire was devel-
oped. This method of data collection was 
chosen because it allowed for a large 
quantity of data to be collected from a 
broad range of people across, irrespective 
of geographical location, in a short period 
of time. Data included in the questionnaire 
generated from media sources (quotes, 
television reports, and a case study on a 
life-saving pharmaceutical) was condensed 
and summarised to ensure ease of under-
standing by respondents. The question-
naire was distributed principally via the 
social media platforms, Facebook and 
Twitter. All respondents were assumed to 
be over the age of 18, and this was the only 
participation criteria. Multimedia clips 
were summarised into condensed forms to 
ensure ease in understanding and reduce 
the questionnaire's completion time. 
Ethical Considerations
Ethical approval for an online anonymous 
questionnaire was obtained from the Keele 
University CPS Student Ethics Committee. 
Question 15 (Case Study: Part A and B) of 
the questionnaire referred to a drug used 
to treat Hepatitis C. Given the stigmatism 
associated with Hepatitis C, the decision 
was taken to not directly reference Hepati-
tis C in Q15 (Marinho and Barrieram, 2013) 
thereby preventing any impact on 
responses.
Data Analysis
In total, 64 responses were recorded. All of 
which were a mix of qualitative and quanti-
tative data and were coded appropriately. 
Where respondents failed to answer the 
questionnaire in a serious manner (one 
respondent matched this criteria), that 
data was excluded from the ﬁnal data 
analysis. Graphs were not used in this study 
due to the length and detail of responses, 
as well as the quantity of qualitative 
responses, although they were used to 
present the demographic information.
Qualitative and Quantitative Data
For the open survey questions, responses 
were grouped under common themes, 
using the method described by Thomas 
(2006). In brief, all responses were read, 
condensed to highlight their key themes, 
and links between these and the research 
questions were established. Responses of 
similar themes were then grouped under 
one, broader, umbrella theme. For the 
multiple choice 'Y/N' questions, the results 
were grouped, tabulated, and analysed as 
previously outlined under Qualitative 
Data. 
Analysis of the complete data revealed a 
higher proportion of female respondents 
than male respondents (Figure 2). This 
disparity meant that gender-based analysis 
was not possible. Additionally, analysis of 
the data demonstrated the majority of 
respondents originated from the UK (n = 
43, 83%), with the remaining participants 
(n = 18, 17%) originating mostly from the 
USA (Figure 3). Given the inequitable 
distribution of participants' geographical 
locales, location-based analysis was also 
not undertaken. Had a more equitable 
distribution, in terms of participant gender 
and location, been achieved within the 
data, additional analysis focussing on these 
attributes may have been possible. 
Results and Discussion
The results from the responses (n = 64) to 
the questionnaire were analysed, as 
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 What is your gender?
Female Male Prefer not to say
Where are you from?
United Kingdom
United States of America
Spain
Germany
Australia
India
Figure 2: Gender of Respondents
Figure 3: Geographical Location of 
Respondents
What is a “Pharmaceutical Patent”?
As part of Q7, respondents were asked to 
provide their own deﬁnition of a pharma-
ceutical patent. The majority of responses 
contained considerable detail although 
some respondents replied “I don't know” or 
similar. Overall, 17% of qualifying respon-
dents did not know what a patent was (in 
the context of the pharmaceutical indus-
try), see Table 1. The results were distilled 
into essentially whether the respondents 
appeared to know what a pharmaceutical 
patent was, or not. Where responses were 
grouped as 'don't know', the respondent 
either explicitly stated that they did not 
know what a patent was, or they gave an 
entirely wrong deﬁnition. As a result, no 
answer was considered 'wrong', unless it 
deviated substantially in theme. Those 
that were grouped as “did not understand 
the question” either gave reference to 
medical patients, not patents, or provided 
an answer such as “a patent on medica-
tions?” (Female, 18-24, level 8). 
After reviewing all answers, it was con-
cluded that the question could have been 
more carefully worded for better sense. 
For the purpose of Table Two, “don't know” 
and “did not understand the question” 
were combined for simplicity. The general 
trend of the data captured by Q7 was that a 
higher level of education (Figure 4) led to a 
better understanding of patents. Gradu-
ates (Level 6) and post-graduates (Level 7) 
generally had a better understanding. 
Curiously, more of the Level 8 respondents 
did not know what a patent was, although 
this may be due to sample size. Overall, the 
trend was that a lower level of education 
resulted in a lower understanding of what a 
patent is: 81.8% of the people who did not 
know what a patent was were aged 18-24 and 
studying at undergraduate level, with the 
remaining two respondents having either Level 
1 or Level 7 qualiﬁcations (Figure 5).  
The majority of respondents could deﬁne a 
What is the highest level of 
educa on you have 
completed? 
Lvl. 1 Lvl. 2 Lvl. 3 Lvl. 4 Lvl. 5
Lvl. 6 Lvl. 7 Lvl. 8 PGCE SOR
Figure 4: Highest Educational 
Qualiﬁcation of Respondents 
outlined under the Materials and Methods.
5What is your age?
18-24 25-34 35-44 45-54
55-64 65-74 75+
Figure 5: Age of Respondents
“patent” with varying levels of detail, 
describing the purpose and function of a 
patent in the process, with points such as 
“time-limited” and “commercial owner-
ship”. However, the understanding the 
diﬀerences between a patent, trademark, 
and copyright was less clear with many 
respondents using the terms interchange-
ably in their responses. Each prevent 
varying degrees of copying and property 
infringement. The distinction between 
these terms is purely academic however, 
with the key aspect of all three terms being 
that they all relate to diﬀerent stages in a 
pharmaceutical's lifespan (Termini and 
Miele, 2013). Once the answer to this 
question had been submitted, respondents 
were provided with a simple deﬁnition of 
what a pharmaceutical patent was. This 
was: 
“A pharmaceutical 
patent is a legal docu-
ment, lasting 20 years, 
that protects an inven-
tion for 20 years. This 
allows pharmaceutical 
companies to develop, 
test, market and sell new 
pharmaceuticals without 
competition. Once the 20 
years has passed, the 
knowledge enters the 
public domain, and 
smaller companies can 
sell their own versions.”
While the aim of this question was to 
establish whether the public understood 
what a patent is and, importantly, what a 
patent does, it also provided a useful 
insight into how the public perceives the 
industry, speciﬁcally how the industry may 
use patents for substantial ﬁnancial gain as 
well as protecting their intellectual prop-
erty. 
The key point theme emerging from 
responses to this question was that the 
pharmaceutical industry uses the patent 
system to procure a considerable proﬁt, 
rather than the commonly held belief that 
it is a force for promoting innovation and 
scientiﬁc development in the drug industry 
(Eisenberg, 2003). While the original goal 
of patent system utilised in the US by the 
FDA was to limit and prevent access to 
fraudulent products through market 
exclusivity, the system has since evolved; 
the patent system plays a pivotal role in 
ensuring that innovation is driven, leading 
to a substantial increase in R&D funding in 
recent years (Eisenberg, 2007).
How much does developing a new drug 
cost?
This question aimed to gauge the extent to 
which respondents understood the cost of 
developing a new drug which, according to 
Sullivan (2019), is estimated to cost $2.6 
billion. Responses to this question varied 
considerably, with values ranging from 
thousands of pounds to billions, as outlined 
in Table 3. Respondents were given a free 
text answer box, with no prompts for how 
much typical drug development costs 
allowing for a 'true' opinion from respon-
dents to be achieved. When constructing 
the questionnaire, it was anticipated that 
responses would be purely quantitative, 
6Answer # of Respondents  
Protect a company’s intellectual property  2 (3.1%) 
Time-limited monopoly  1 (1.6%) 
Protection of a pharamceutical  5 (7.8%) 
Don’t know 11 (17.2%)  
Prevents copying  7 (10.9%) 
Shows ownership  of a pharmaceutical  5 (7.8%) 
Time-limited exclusivity  3 (4.7%) 
Commercial ownership (time -limited) 7 (10.9%) 
Did not understand the question  13 (20.3%)  
Time-limited ownership  1 (1.6%) 
Commercial ownership  3 (4.7%) 
Trademark  2 (3.1%) 
Copyright  3 (4.7%) 
Guarantees exclusivity  1 (1.6%) 
 Table 1: Tabulated Responses to Q7.
 What is a “ Pharmaceutical Patent ”? 
Education  Understood  Did Not Understand  
Level 1  0 1 
Level 2 0 0 
Level 3 3 1 
Level 4 7 5 
Level 5 7 9 
Level 6 12 3 
Level 7 9 2 
Level 8 2 3 
 Table 2: Education Level of Respondent and Understanding of Patents. 
7Answer  # of Respondents  
Don’t know  1 
Depends  1 
A lot 4 
Thousands  13 
Millions  34 
Billions  9 
Millions to Billions  2 
 Table 3: Responses to Q8. 
with rough cost estimates stated. How-
ever, when responses were analysed, it 
was found that 92% of respondents gave 
reasoning behind their answers, resulting 
in a mix of quantitative and qualitative 
data. 
  While none of the responses correctly 
identiﬁed the estimated price (14% 
correctly identiﬁed the price was in the 
billions), a common theme from the free-
text answers was that you cannot put a 
price on a human life. That aside, many 
respondents correctly identiﬁed that 
developing a novel drug is time-consuming 
and costly, with multiple stages. Indeed, 
the majority stated (>70%) that while 
research and development costs will vary 
for diﬀerent drugs; the average cost is 
high. All levels of education had a good 
grasp of this, and many knew the speciﬁcs 
in the development process as justiﬁca-
tion for their answer. This further appears 
to suggest that not knowing a precise legal 
deﬁnition of 'patent' does not mean there 
is a lack of understanding of the key ideas 
(Pauls, 2017).
“Include the cost of 
hiring engineers, 
doctors, & test subjects. 
As well as paying for 
facilities to test new 
drugs”
Female, aged 18-24, 
level 5
As media coverage is prominent, with 
some reports being branded as inaccurate 
and over-exaggerative (Dolak and Blaine, 
2008), the common media representation 
of patents may be the source of people's 
knowledge in this aspect.
What do you think is the main goal of a 
multi-national pharmaceutical com-
pany?
A common theme in response to this 
question was that the pharmaceutical 
industry is only out to make a proﬁt. There 
was no mention of curing illnesses, or 
increasing the accessibility of life-saving 
pharmaceuticals, only that the goal is to 
become an “industry leader”, maximising 
proﬁt, and this was mirrored across the 
majority of responses. The use of patient 
also suggests vulnerability of the user, 
truly mirroring the words Latin origins 
(Neuberger, 1999).
“The creation of drugs 
for the proﬁt of the 
people”
Female, aged 18-24, 
level 5
8That being said, there was also a number 
of positive responses, highlighting that 
the pharmaceutical industry may not have 
these ulterior motives, and are primarily 
health-focused, not just working for a proﬁt. 
The above response suggested that there can 
be a focus on proﬁt, while still providing an 
adequate health service. It was identiﬁed that 
while there is the obvious goal of making a 
proﬁt, the pharmaceutical industry is 
ultimately providing a service that treats 
illness and improve accessibility, even if it 
isnt seen as working for everyone. 
Nearly all of the positive responses were 
from undergraduates aged 18-24 suggest-
ing that younger generations have a more 
positive view of the industry, perhaps due 
to less negative, or even fewer, experi-
ences because of their age. Interestingly, 
there were no responses talking about 
how while patients should be the priority, 
proﬁt is vital in the development of 
pharmaceuticals; the industry is funded 
by private donors and shareholders who 
are unlikely to provide funding in the 
future if they do not see a return on their 
investments, stagnating the drug market 
(Taylor, 2015).
Pharmaceutical companies have a 
responsibility to human life.
The tenure of Henry Gadsden, the then 
CEO of Merck and Co. from 1965-1975 
marked the dawn of the publicly per-
ceived modern proﬁt driven pharmaceuti-
cal industry. Under his guidance, Merck's 
client base increased, allowing for a 
quadrupled proﬁt growth with earnings 
exceeding $225 million (Hbs.edu., 2019). 
This can be perceived as setting a danger-
ous precedent for the modern pharmaceu-
tical industry in which everyone is a 
patient and patient's equal proﬁt. Merck 
further increased research and develop-
ment spending up to $1 billion after 
Gadsden's retirement.
“Sell pills to everyone 
and make prescription 
drugs as normal and 
matter of fact as having 
a stick of chewing gum”
(Gadsden, 1971)
  
After reading that quote, do you now think  
pharmaceutical companies have a 
responsibility to human life?  
The pharmaceutical 
industry has a 
responsibility to 
human life  
Original response  Yes No 
Strongly Agree  22 19 3 
Agree 31 28 3 
I don’t know  2 2 0 
Disagree  7 0 7 
Strongly Disagree  2 2 0 
 Table 4: Q10 Opinion Change Pre/Post-Quote.
9Here, respondents were asked whether 
they believed pharamceutical companies 
had a responsibility to human life. They 
were then shown a quote from Henry 
Gadsden outlining his vision for the future 
of the pharmaceutical industry, and were 
then asked the same question again, with 
all results shown in Table 4.
Progression through the questionnaire saw 
the majority of people (73%) retain their 
original opinions, with the additional 
information either enforcing their opinion, 
or having no eﬀect. In this case, few people 
(12.5%) changed their view on whether the 
pharmaceutical industry had a responsibil-
ity to human life. While the majority did 
remain with their original view, there were 
some notable changes, all of which seemed 
to revolve around proﬁt. 
“They still have a respon-
sibility. They may not 
meet it or take it as 
seriously as they should, 
and they may make 
shortcuts in clinical 
trials, but that doesn't 
remove their responsibil-
ity”
Female, aged 35-44, 
level 6
Notably, it was suggested that while money 
is a major driving force, it is not the entire 
story. The above quote suggested that 
Gadsden only wanted to improve accessi-
bility to pharmaceuticals for everyone who 
needs them, so those who require life-
saving pharmaceuticals can access them as 
easily as someone would pick up a packet 
of gum; WHO predicts improving assess to 
essential medicines could save 10 million 
lives every year (Cohen, Mrazek and 
Hawkins, 2007). While a proﬁt may be 
made in the process, there is a legal 
requirement that they must improve the 
overall quality of life and making a larger 
proﬁt does not limit a drug's eﬀectiveness.
Case Studies
As part of this study, participants were 
asked to consider two case studies (A and 
B), both of which explored the manufactur-
ing cost and market price for a Hepatitis C 
treatment that cures the condition fully. As 
outlined in the Materials and Methods, 
while the case studies were designed using 
hepatitis C, it was decided to avoid any 
direct mention of the condition given the 
continuing stigmatism around hepatitis. 
Case Study A
On average, the NHS pays £35,000 for a 12-
week course of a drug which completely 
cures a chronic condition, with few side 
eﬀects, for a single patient. This cost 
covers just the purchase of the drug from 
the parent pharmaceutical company 
(Freeman and Hill, 2016; Newsnight, 
2016). 
“While it is impossible to 
reduce (the price of) 
human suﬀering to a 
mere cost- beneﬁt 
analysis, it is likely that 
curing a chronic condi-
tion (with minimal side 
eﬀects) saves the 
economy far more than 
the £35,000 price the 
NHS pays.”
Male, aged 18-24, level 4
When asked if this price was justiﬁed, more 
than half (67%) of participants concluded 
that this cost represents value for money 
on the basis that it removes the need for 
future treatment while reducing any 
future impacts on healthcare services 
(Harris et al., 2014), ultimately saving 
money in the long run. What was not 
mentioned in the question however, was 
that this treatment is not universally 
provided by the NHS due to its cost, with 
treatment being considered on an individ-
ual basis, forcing the majority of patients 
to ﬁnd other means of procurement 
(Newsnight, 2016). As a result of this, 
10
people are turning to online buyer's clubs, 
where generic versions of these block-
buster drugs are provided at a fraction of 
the healthcare market price; estimated 
Hepatitis C treatment through a buyer's 
club is estimated to cost an individual 
seeking treatment £750, compared to the 
NHS's cost of £35,000 (Newsnight, 2016). 
Case Study B
The same drug costs roughly £100 to be 
manufactured, for a 12-week course, for a 
single patient. After learning the cost of 
this particular drugs cost to manufacture, 
participants were then asked again if they 
believed the cost was justiﬁed, responses 
to this question are outlined in Table 5. 
After this, two questions surveyed respon-
dent's preferences for over-the-counter 
painkiller preference, with chemical 
similarities between standard branded and 
own-brand/generic options provided. 
Is this price justified?  
The high cost of this drug is justified, as it makes up for years 
of research and development costs  
 Original  
Strongly 
Agree  
Agree  
I don’t 
know 
Disagree  
Strongly 
Disagree  
Yes 43 5 17 15 5 2 
No 21 0 4 6 7 3 
 
Table 5: Opinion Change in Response to Case Study B.
Participants were then asked whether they 
purchased over-the-counter or branded 
painkillers and, after learning of the 
diﬀerences and similarities in their 
activity, whether they would continue to 
purchase one or the other (Table 6) with 
92%  o f  re spondents  buy ing  own-
brand/generic painkillers, with the same 
reasons being given consistently, essen-
tially: same drug, lower price. This sup-
ports the conclusions made by Halme et al. 
(2009), where price was the predominant 
factor in buying preference.
When provided with a chemical breakdown, 
95% of people who said that they originally 
bought own-brand/generic painkillers said 
they would continue to do so, stating that the 
information provided conﬁrmed their beliefs. 
There was a small number (3) of respondents, 
who previously said they bought own-
brand/generic versions. Interestingly, of the 
  Do you think you will conti nue to buy the 
same branded or own -brand/generic 
painkillers in the future?  
 When buying over -
the-counter 
painkillers, do you 
go for branded or 
own-brand/generic 
variants?  
Yes No 
Own-brand/generic  59 56 3 
Branded  5 4 1 
 
Table 6: Change in Buying Preference. 
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original respondents who said they purchased 
branded over-the-counter painkillers (5), four 
admitted they would continue, stating they 
felt safer with the big brands, and that they 
know they work; an example of prior experi-
ences dictating how choices are made 
(Halme, Linden and Kaaria, 2009). Only one 
person said they would no longer purchase 
branded after seeing the information 
stating that “there is no diﬀerence” 
(Male, aged 18-24, level 4).
A 'branded' pharmaceutical must undergo 
extensive development and clinical trials 
to show it is safe and is often developed to 
have a certain pharmacokinetic proﬁle . In 
1990, it cost approximately $1.3 billion to 
develop a blockbuster pharmaceutical 
compared to $603,000 for a generic drug 
(Reiﬀen and Ward, 2005) (Chawla et al., 
2014). Studies have shown that there is 
little chemical diﬀerence between over-
the-counter painkillers of the same 
purpose (Jadge et al., 2014) and work the 
same (Studman, 2019), although not are 
all exactly physico-chemically equivalent 
to their branded equivalent (Okunlola, 
Adegoke and Odeku, 2009). Some brands 
are targeted at speciﬁc conditions, and 
while they may have similar ingredients 
resulting in little diﬀerence between the 
options available, people are more likely 
to buy a painkiller targeted at migraines 
than a generic paracetamol or ibuprofen 
(Pearl, 2015).
While it is important to understand the 
diﬀerences and similarities between over-
the-counter painkillers and other life-
saving pharmaceuticals, it is equally as 
important to understand that patent 
protection on a pharmaceutical prevents 
any company not listed on the patent 
document from selling their own version 
of the drug until the patent expires 
(Huskamp et al., 2008); after this time, 
generic equivalents will most likely 
become available at a reduced market 
price.
Crigger et al. (2009) suggested that the 
education level of the consumer would 
directly impact buying choice; in this 
study, the sample size was not large 
enough to make a suitable comment on 
whether this was the case. Responses 
show a comparison between education 
and buying preference however, likewise, 
with age, there was no notable variation. 
This is not to say that they have no impact, 
just that this is not the case in this study. 
That being said, as the majority of respon-
dents were university students, all of 
whom will have an interest in healthy 
lifestyles because of their ages, this is 
perhaps something that inﬂuences their 
purchasing choice, something which is 
mirrored in Halme et al. (2009) study.
Participants in this study were also asked, 
more generally, as to whether they 
believed the patent system worked (Table 
7). This question was deliberately open-
ended and vague in what it wanted as an 
answer; the aim was to establish whether 
participants understood the patent 
Strongly Agree  0 
Agree  16 
I don’t know  32 
Disagree  11 
Strongly Disagree  5 
 Table 7: Views of the functionality of the patent system currently used in the 
pharmaceutical industry.
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system, and whether its function in pro-
tecting and supplying medication is 
fulﬁlled. Essentially, is the public edu-
cated enough on the patent system, 
enough to know when it works and when it 
fails? 
Notably, half of respondents (50%) did not 
know whether the patent system works, 
stating they were not educated enough in 
the area to give an opinion. Age, educa-
tion, and location had no impact on this 
opinion of the system; people have very 
little understanding in the area. Those 
that disagree, claim that the system isnt 
suitable nor sustainable, and does not 
work for its intended purpose, essentially 
holding vulnerable users to ransom; this is 
mirrored by the industry's critics, 
although no-one has provided a feasible 
alternative (Taylor, 2015). 
Conclusion
This study aimed to explore how the 
provision of information has the potential 
to alter and inﬂuence the public's opinion 
of the pharmaceutical industry. The public 
has an overall mixed perception of the 
pharmaceutical industry with the major-
ity believing it is a money-centric indus-
try. Education appeared to have an impact 
on understanding and views of the phar-
maceutical industry, although there was 
no clear link between this and over-the-
counter painkiller buying preference, 
with the majority buying generic versions 
in any case. Age also appeared to have 
little impact on generic/branded drug 
purchasing preference. Cost was found to 
be the biggest inﬂuencer, as previously 
found by Crigger et al. (2009), with many 
respondents understanding the similari-
ties and diﬀerences between the avail-
able options. The information provided to 
participants around research and devel-
opment costs did appear to have an 
impact, albeit primarily reinforcing 
previously held beliefs. Half of respon-
dents did not know whether the patent 
system works, stating a lack of under-
standing. This study could be taken fur-
ther to understand the public's under-
standing, or lack thereof, of the patent 
system, and how it inﬂuences and impacts 
the running of the industry. A study into 
the extent of brand loyalty of the public 
may also yield interesting results. In 
conclusion, this study explored the extent 
to which diﬀerent factors aﬀect and 
impact the public's perceptions and 
opinions of the pharmaceutical industry, 
despite the limitations discussed below, a 
basis has been established for future 
research in the area to be conducted.
Limitations
This paper aimed to understand the 
impact of demographics on the public's 
understanding of the pharmaceutical 
industry; this was partially successful, 
although the main downfall arose from 
the overall sample size. As this was a 
ﬁnal year undergraduate research 
project, survey reach was limited to 
people the researcher had access to 
through social media, and the people 
who could access the shared social 
media posts. As a result of this, reaching 
people in other countries (which was 
one of the target demographics to be 
collected) was not as easy, meaning the 
UK had the largest pool in the results. A 
similar issue arose with both gender 
(more female respondents than male 
respondents) and age (primarily 
university students in level 4 to level 6 
of their education). These issues could 
have been rectiﬁed by keeping the 
survey live for a longer period of time 
allowing for more people to answer and 
leading to a more varied sample pool. 
Other ways of sharing the survey than 
just social media and word of mouth 
would have been beneﬁcial for getting a 
more varied data set.
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